Imperial College London’s Professor of Hepatology, Mark Thursz, has been appointed to the Scientific Advisory Board of HepaTx (the SAB), a biotechnology company focused on cell therapy liver diseases
Palo Alto, CA – London, UK - Imperial College London’s Professor of Hepatology, Mark Thursz, has been appointed to the Scientific Advisory Board of HepaTx (the SAB), a biotechnology company focused on cell therapy liver diseases. Professor Thursz is Head of the Department of Metabolism, Digestion & Reproduction in the Faculty of Medicine at Imperial College London and a clinical hepatologist at St Mary’s Hospital.
Professor Thursz’s accomplishments include work on genetic susceptibility in viral hepatitis, the natural history of viral hepatitis, and the factors involved in disease progression. Other work focused on the role of the coagulation system in hepatic fibrogenesis. In 2011, he launched the PROLIFCA program, which demonstrated the feasibility and cost-effectiveness of community-based screening for viral hepatitis in sub-Saharan Africa, impacting WHO policy. Additionally, Professor Thursz runs a translational research program in alcohol-related liver disease and led the Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial, which explored the effectiveness of existing treatments for alcoholic hepatitis.
Thursz’s appointment to the HepaTx SAB will further enhance the company’s capabilities in developing new treatments for liver disease. His expertise in hepatology and drug development will be invaluable in guiding HepaTx’s R&D efforts. As Director of the Imperial College Biomedical Research Centre and Trust Research Director for Imperial College Healthcare NHS Trust, Professor Thursz brings a wealth of experience to the board. His extensive experience in hepatology, research, and drug development assists HepaTx’s efforts to develop innovative treatments for liver disease, benefiting patients worldwide.
HepaTx’s CEO, Eric Schuur, welcomed Professor Thursz to the board, saying, “We are delighted to have Professor Thursz join our SAB. His expertise in liver disease and drug development will be invaluable in guiding our research efforts and advancing our mission to develop innovative treatments for liver disease.”
Commenting on his appointment to the board, Professor Thursz said, “I am excited to join HepaTx’s SAB and contribute to the development of new treatments for liver disease. The company’s innovative approach to liver disease therapy and its commitment to improving patient outcomes make it an exciting opportunity for me.”
About HepaTx
HepaTx is a cell therapy and regenerative medicine company developing cell-based treatments for late-stage liver disease, a highly underserved and cost-intensive market. To learn more, visit our website, Hepatx.com, and follow us on Twitter, @hepatx, and LinkedIn.
Contact:
HepaTx
Claudia Preziosi
cpreziosi@hepatx.com